⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127194 | 0.80 | — | — | |
| SCHEMBL536980 | 0.73 | DPP4 (0.34) | — | |
| SCHEMBL536971 | 0.68 | LRRK2 (0.31) | — | |
| SCHEMBL6712707 | 0.68 | — | — | |
| SCHEMBL4860847 | 0.65 | CHEK1 (0.36) | — | |
| SCHEMBL536868 | 0.65 | — | — | |
| SCHEMBL8884479 | 0.65 | — | — | |
| SCHEMBL7938941 | 0.56 | CDK1 (0.45) | — | |
| SCHEMBL14864520 | 0.54 | PDE10A (0.41) | — | |
| SCHEMBL3444583 | 0.52 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | claimed |
| WO-2023167094-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2023-09-07 | — | — | WO | claimed |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-04-20 | — | — | US | claimed |
| EP-4108670-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| EP-4108262-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115135658-A | Bridged nucleoside and nucleotide using the same | 国立大学法人大阪大学 | 2022-09-30 | — | — | CN | claimed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | claimed |
| WO-2022004388-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2022-01-06 | — | — | WO | claimed |
| EP-3925965-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-22 | — | — | EP | claimed |
| EP-3919501-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-08 | — | — | EP | claimed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | claimed |
| EP-1486504-A1 | NUCLEOSIDE ANALOGUES WHOSE SUGAR MOIETIES ARE BOUND IN S-FORM AND OLIGONUCLEOTIDE DERIVATIVES COMPRISING NUCLEOTIDE ANALOGUES THEREOF | Imanishi, Takeshi (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1481983-A1 | NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE DERIVATIVE COMPRISING NUCLEOTIDE ANALOGUE THEREOF | Imanishi, Takeshi (JP) | 2004-12-01 | — | — | EP | claimed |
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | claimed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | claimed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | claimed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | claimed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | claimed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | claimed |